

(43) International Publication Date
14 July 2011 (14.07.2011)

PCT

(10) International Publication Number
WO 2011/084437 A1

(51) International Patent Classification:

C07D 249/10 (2006.01) **A61P 25/00** (2006.01)
A61K 31/4196 (2006.01)

(21) International Application Number:

PCT/US2010/060371

(22) International Filing Date:

15 December 2010 (15.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09382290.6 21 December 2009 (21.12.2009) EP
61/305,239 17 February 2010 (17.02.2010) US(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **MONN, James, Allen** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **PRIETO, Lourdes** [ES/ES]; c/o Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, 46285 (US). **TABOADA MARTINEZ, Lorena** [ES/ES]; c/o Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, 46285 (US). **MONTERO SALGADO, Carlos** [ES/ES]; c/o Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, 46285 (US). **SHAW, Bruce William** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US).(74) Agents: **HOSTETTLER, Danica** et al.; Eli Lilly and Company, Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: MGLU2 AGONISTS



(57) Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder. The novel agonists are represented by the formula.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*